Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pilulka Lekarny ASXPRA:PINK 50 5-Year Yield-on-Cost % is 0.00 as of Aug. 24, 2026. GuruFocus rates XPRA:PINK with a GF Score™ of 50/100 and a GF Value™ of Kč110.59 (Fairly Valued). The stock has 6 warning signs investors should review. Among 278 Healthcare Providers & Services companies, Pilulka Lekarny AS ranks worse than 359711.87% on this metric.
Pilulka Lekarny AS's yield on cost for the quarter that ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Pilulka Lekarny AS's 5-Year Yield-on-Cost % or its related term are showing as below:
XPRA:PINK's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.94 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Pilulka Lekarny AS (XPRA:PINK) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Pilulka Lekarny AS 5-Year Yield-on-Cost % Related Terms
Pilulka Lekarny AS 5-Year Yield-on-Cost % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Pilulka Lekarny AS's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pilulka Lekarny AS 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pilulka Lekarny AS's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Pilulka Lekarny AS's 5-Year Yield-on-Cost % falls into.
Pilulka Lekarny AS 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Pilulka Lekarny AS (XPRA:PINK) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 24, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pilulka Lekarny AS and its competitors. According to the industry distribution chart, Pilulka Lekarny AS ranks #999999 out of 278 companies in the Healthcare Providers & Services industry.
Is Pilulka Lekarny AS's 5-Year Yield-on-Cost % too high?
Pilulka Lekarny AS's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Pilulka Lekarny AS ranks #999999 out of 278 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Pilulka Lekarny AS has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pilulka Lekarny AS's 5-Year Yield-on-Cost % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pilulka Lekarny AS ranks #999999 out of 278 companies for 5-Year Yield-on-Cost %. This places Pilulka Lekarny AS in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.94, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pilulka Lekarny AS and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pilulka Lekarny AS's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pilulka Lekarny AS stock overvalued right now?
Based on GuruFocus' analysis, Pilulka Lekarny AS (XPRA:PINK) is currently considered Fairly Valued. The stock's GF Value™ is Kč110.59, compared to a current price of Kč119.00 — trading 7.6% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Pilulka Lekarny AS's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Pilulka Lekarny AS (XPRA:PINK), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pilulka Lekarny AS (XPRA:PINK) Overvalued in 2026?
Based on GuruFocus' analysis, Pilulka Lekarny AS stock appears to be overvalued.
The current stock price of Kč119.00 is trading 7.6% above its estimated GF Value™ of Kč110.59.
GuruFocus considers Pilulka Lekarny AS to be Fairly Valued.
Key valuation signals for XPRA:PINK:
5-Year Yield-on-Cost %: 0.00
GF Value™: Kč110.59 vs. price of Kč119.00 (7.6% above fair value)
No single metric tells the full story. See the XPRA:PINK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
50GF Score
Get the complete analysis for XPRA:PINK
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPRA:PINK has been successfully added to your 
